Literature DB >> 2573104

D1- and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics.

L Farde1, F A Wiesel, A L Nordström, G Sedvall.   

Abstract

Using positron emission tomography and the selective ligands 11C-SCH23390 and 11C-raclopride, central D1- and D2-dopamine receptor occupancy was determined in schizophrenic patients treated with clinical doses of classical and atypical neuroleptics. Treatment with ten chemically distinct classical neuroleptics resulted in a 65-89% occupancy of D2-dopamine receptors. This finding represents strong support for the hypothesis that the mechanism of action of antipsychotic drugs is indeed related to a substantial degree of D2-dopamine receptor occupancy. In two patients treated with the atypical neuroleptic clozapine, 300 mg b.i.d. and 150 mg b.i.d., the D2-dopamine receptor occupancy was 65 and 40%, respectively. D1-dopamine receptor occupancy was determined in six antipsychotic drug-treated patients. No D1-dopamine receptor occupancy was found in patients treated with sulpiride and perphenazine, compounds known to be selective D2-dopamine receptor antagonists. The highest D1-dopamine receptor occupancy, 42%, was found in the patient treated with clozapine 150 mg b.i.d. The effects of the atypical neuroleptic clozapine may be related to a combined effect on both D1- and D2-dopamine receptors.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2573104     DOI: 10.1007/BF00442555

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  18 in total

Review 1.  Multiple receptors for dopamine.

Authors:  J W Kebabian; D B Calne
Journal:  Nature       Date:  1979-01-11       Impact factor: 49.962

2.  Imaging of neurotransmitter receptors in the living human brain.

Authors:  G Sedvall; L Farde; A Persson; F A Wiesel
Journal:  Arch Gen Psychiatry       Date:  1986-10

3.  Preparation of 11C-labelled SCH 23390 for the in vivo study of dopamine D-1 receptors using positron emission tomography.

Authors:  C Halldin; S Stone-Elander; L Farde; E Ehrin; K J Fasth; B Långström; G Sedvall
Journal:  Int J Rad Appl Instrum A       Date:  1986

4.  Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs.

Authors:  I Creese; D R Burt; S H Snyder
Journal:  Science       Date:  1976-04-30       Impact factor: 47.728

5.  Some atypical neuroleptics inhibit [3H]SCH 23390 binding in vivo.

Authors:  P H Andersen; E B Nielsen; F C Grønvald; C Braestrup
Journal:  Eur J Pharmacol       Date:  1986-01-14       Impact factor: 4.432

6.  Akathisia variants and tardive dyskinesia.

Authors:  T R Barnes; W M Braude
Journal:  Arch Gen Psychiatry       Date:  1985-09

7.  Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET.

Authors:  L Farde; H Hall; E Ehrin; G Sedvall
Journal:  Science       Date:  1986-01-17       Impact factor: 47.728

8.  Stereoselective binding of 11C-raclopride in living human brain--a search for extrastriatal central D2-dopamine receptors by PET.

Authors:  L Farde; S Pauli; H Hall; L Eriksson; C Halldin; T Högberg; L Nilsson; I Sjögren; S Stone-Elander
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

9.  Imaging dopamine receptors in the human brain by positron tomography.

Authors:  H N Wagner; H D Burns; R F Dannals; D F Wong; B Langstrom; T Duelfer; J J Frost; H T Ravert; J M Links; S B Rosenbloom; S E Lukas; A V Kramer; M J Kuhar
Journal:  Science       Date:  1983-09-23       Impact factor: 47.728

10.  An open label trial of raclopride in acute schizophrenia. Confirmation of D2-dopamine receptor occupancy by PET.

Authors:  L Farde; F A Wiesel; P Jansson; G Uppfeldt; A Wahlen; G Sedvall
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

View more
  58 in total

1.  Increased baseline occupancy of D2 receptors by dopamine in schizophrenia.

Authors:  A Abi-Dargham; J Rodenhiser; D Printz; Y Zea-Ponce; R Gil; L S Kegeles; R Weiss; T B Cooper; J J Mann; R L Van Heertum; J M Gorman; M Laruelle
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

2.  Understanding schizophrenia.

Authors:  L S Pilowsky
Journal:  BMJ       Date:  1992-08-08

Review 3.  Clinical profile of clozapine: adverse reactions and agranulocytosis.

Authors:  J A Lieberman; A Z Safferman
Journal:  Psychiatr Q       Date:  1992

4.  Time course of D2-dopamine receptor occupancy examined by PET after single oral doses of haloperidol.

Authors:  A L Nordström; L Farde; C Halldin
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

Review 5.  Clozapine--pharmacokinetic investigations and biochemical effects in man.

Authors:  M Ackenheil
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

6.  Clozapine binds preferentially to cortical D1-like dopamine receptors in the primate brain: a PET study.

Authors:  Yuan-Hwa Chou; Christer Halldin; Lars Farde
Journal:  Psychopharmacology (Berl)       Date:  2006-01-05       Impact factor: 4.530

Review 7.  Positron emission tomography and single-photon emission computed tomography in central nervous system drug development.

Authors:  David J Brooks
Journal:  NeuroRx       Date:  2005-04

8.  Sensorimotor dysfunction of grasping in schizophrenia: a side effect of antipsychotic treatment?

Authors:  D A Nowak; B J Connemann; M Alan; M Spitzer
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-05       Impact factor: 10.154

9.  Clozapine's functional mesolimbic selectivity is not duplicated by the addition of anticholinergic action to haloperidol: a brain stimulation study in the rat.

Authors:  E L Gardner; L S Walker; W Paredes
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

10.  SERT and NET occupancy by venlafaxine and milnacipran in nonhuman primates: a PET study.

Authors:  Akihiro Takano; Christer Halldin; Lars Farde
Journal:  Psychopharmacology (Berl)       Date:  2012-10-23       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.